Vitamin K2 and Muscle Weakness in Type 2 Diabetes (SARK2)
Effects Vitamin K2 on Muscle Mass and Function in People With Muscle Weakness and Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Stuart Gray
- Phone Number: 01413302569
- Email: stuart.gray@glasgow.ac.uk
Study Locations
-
-
-
Kuwait City, Kuwait, 15462
- Recruiting
- Dasman Diabetes Institute
-
Contact:
- Ebaa AlOZairi
-
Principal Investigator:
- Ebaa AlOzairi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Physician confirmed type 2 diabetes.
- Age >/= 40 years
- No changes in anti-diabetic medication in the last 3 months.
- Muscle weakness (grip strength <27kg and females <16kg)
Exclusion Criteria:
- BMI of 45 or higher
- BP of 160/100mmHg or higher
- Cancer or cancer that has been in remission <5 years
- Any medical condition that prevents participants from exercising safely
- On anticoagulant therapy
- Currently consuming vitamin K2 supplements
- Current smoker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
micro-crystalline cellulose placebo (one 380 mg tablet per day)
|
Placebo
|
|
Active Comparator: Vitamin K2
micro-crystalline cellulose (one 380 mg tablet per day) where vitamin K2 (K2VITAL® 0.2% DELTA powder) is mixed into the formulation to a final vitamin K2 concentration of 240 μg/tablet
|
Vitamin K2
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Grip Strength
Time Frame: Baseline to one year
|
Change in Grip Strength
|
Baseline to one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SPPB
Time Frame: Baseline to one year
|
Change in Short Performance Physical Battery Test
|
Baseline to one year
|
|
HbA1c
Time Frame: Baseline to one year
|
Change in glycated haemoglobin
|
Baseline to one year
|
|
Blood Pressure
Time Frame: Baseline to one year
|
Change in blood pressure
|
Baseline to one year
|
|
Body Mass
Time Frame: Baseline to one year
|
Change in body mass
|
Baseline to one year
|
|
Lean Mass
Time Frame: Baseline to one year
|
Change in lean mass
|
Baseline to one year
|
|
Body Fat
Time Frame: Baseline to one year
|
Change in body fat
|
Baseline to one year
|
|
BMC
Time Frame: Baseline to one year
|
Change in bone mineral content
|
Baseline to one year
|
|
BMD
Time Frame: Baseline to one year
|
Change in bone mineral density
|
Baseline to one year
|
|
Vitamin K status
Time Frame: Baseline to one year
|
Change in vitamin K status
|
Baseline to one year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ebaa AlOzairi, Dasman Diabetes Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Mellitus
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Diabetes Mellitus, Type 2
- Muscle Weakness
- Paresis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Fibrin Modulating Agents
- Micronutrients
- Vitamins
- Antifibrinolytic Agents
- Hemostatics
- Coagulants
- Vitamin K
- Vitamin K 2
Other Study ID Numbers
Other Study ID Numbers
- RA HM-2021-015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.